| [1] | 段纪俊,严亚琼,杨念念,等.中国恶性肿瘤发病与死亡的国际比较分析[J].中国医学前沿杂志,2016,8(7):17. |
| [2] | HARTGRINK HH,VAN DE VELDE CJ.Status of extended lymph node dissection:locoregional control is the only way to survive gastric cancer[J].J Surg Oncol,2005,90(3):153. |
| [3] | KARIMI P,ISLAMI F,ANANDASABAPATHY S, et al.Gastric cancer:descriptive epidemiology,risk factors,screening,and prevention[J].Cancer Epidemiol Biomarkers Prev,2014,23(5):700. |
| [4] | MACDONALD JS,SMALLEY SR,BENEDETTI J, et al.Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[J].New Engl J Med,2001,345(10):725. |
| [5] | KIM S,LIM DH,LEE J, et al.An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal-dissecon for adenocarcinoma of the stomach[J].Int J Radiati Oncol Biol Phys,2005,63(5):1279. |
| [6] | LEE J,LIM DH,KIM S, et al.Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:the ARTIST trial[J].J Clin Oncol,2012,30(3):268. |
| [7] | BANG YJ,KIM YW,YANG HK, et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):a phase 3 open-label,randomized controlled trial[J].Lancet,2012,379(9813):315. |
| [8] | HUI WT,MA XB,ZAN Y, et al.Prognostic significance of MiR-34a expression in patients with gastric cancer after radical gastrectomy[J].Chin Med J (Engl),2015,128(19):2632. |
| [9] | GATENBY PA,SHAW C,HINE C, et al.Retrospective cohort study of an enhanced recovery programme in oesophageal and gastric cancer surgery[J].Ann R Coll Surg Engl,2015,97(7):502. |